- -- 30 November 2007
- immatics is laureate in the "2007 STEP Award"
- -- 25 September 2007
- immatics launches Phase 2 study on cancer vaccine IMA901
- -- 06 June 2007
- FierceBiotech names immatics biotechnologies one of the "Fierce 15" biotech companies of 2007
- -- 01 June 2007
- Visit us at the ASCO 2007 Meeting in Chicago
- -- 14 March 2007
- immatics granted orphan drug status for therapeutic cancer vaccine IMA901
- -- 08 February 2007
- immatics receives € 40 million in second round of funding / Largest private biotech financing round in Germany since 2001
immatics is laureate in the "2007 STEP Award"
Tuebingen, Germany, November 30, 2007. Today immatics biotechnologies, a company dedicated to the development of peptide-based immune therapeutics for the treatment of cancers, announced to be laureate in the "2007 STEP Award" in the category "Processes".
The jury was particularly convinced by the exceptionally short pre-clinical development time. For its first product candidate – IMA901 against renal cell cancer – the company took merely 22 months from the analysis of the first tumor samples to commencing vaccination of first patients in a clinical study. Less than a year later immatics was able to conclude this phase 1 study with very promising results. At the end of September 2007, the company started an international Phase 2 study for the cancer vaccine IMA901.
The "STEP Award" is a competition for rewarding high-growth companies in Germany, Switzerland and Austria. The initiators, Infraserv Hoechst and the F.A.Z. Institute, jointly pursue with renowned sponsors the aim of giving companies during their growth phase a significant stimulus for their successful development. Further information on "STEP Award" can be found under www.step-award.de